BioCryst

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BioCryst and other ETFs, options, and stocks.

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. 

CEO
Jon P. Stonehouse
CEOJon P. Stonehouse
Employees
580
Employees580
Headquarters
Durham, North Carolina
HeadquartersDurham, North Carolina
Founded
1986
Founded1986
Employees
580
Employees580

BCRX Key Statistics

Market cap
1.39B
Market cap1.39B
Price-Earnings ratio
-38.15
Price-Earnings ratio-38.15
Dividend yield
Dividend yield
Average volume
9.54M
Average volume9.54M
High today
$6.78
High today$6.78
Low today
$6.44
Low today$6.44
Open price
$6.67
Open price$6.67
Volume
7.57M
Volume7.57M
52 Week high
$11.31
52 Week high$11.31
52 Week low
$6.00
52 Week low$6.00

BCRX News

Nasdaq 3d
BioCryst Soars 6.1%: Is Further Upside Left in the Stock?

BioCryst Pharmaceuticals (BCRX) shares ended the last trading session 6.1% higher at $6.81. The jump came on an impressive volume with a higher-than-average num...

BioCryst Soars 6.1%: Is Further Upside Left in the Stock?
TipRanks 3d
BioCryst’s Strategic Acquisition of Astria Therapeutics and Promising HAE Treatment Drive Buy Rating

BioCryst, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy...

Simply Wall St 3d
BioCryst Pharmaceuticals: Exploring Valuation Following Recent Share Price Declines

BioCryst Pharmaceuticals (BCRX) has seen its stock price fluctuate over the past month, dropping 12%. Returns for the past three months show a steeper decline....

BioCryst Pharmaceuticals: Exploring Valuation Following Recent Share Price Declines

Analyst ratings

91%

of 11 ratings
Buy
90.9%
Hold
9.1%
Sell
0%

More BCRX News

TipRanks 4d
BioCryst price target raised to $26 from $24 at Cantor Fitzgerald

Cantor Fitzgerald analyst Steve Seedhouse raised the firm’s price target on BioCryst (BCRX) to $26 from $24 and keeps an Overweight rating on the shares. BioCry...

TipRanks 4d
BioCryst’s Strategic Acquisition of Astria Therapeutics: Enhancing HAE Portfolio with Navenibart

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on BioCryst. The associated price target remains the same with $30.00. Elevate Your Inve...

TipRanks 4d
BioCryst’s Strategic Acquisition of ATXS: A Catalyst for Long-Term Growth and Profitability

Jefferies analyst Maury Raycroft maintained a Buy rating on BioCryst today and set a price target of $15.00. Elevate Your Investing Strategy: Take advantage of...

TipRanks 4d
Strategic Acquisition of Astria Therapeutics by BioCryst Pharmaceuticals Highlights Potential of Navenibart for HAE Prophylaxis

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Astria Therapeutics and decreased the price target to $13.00 from $23.00. Elevate Your Inves...

Benzinga 4d
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc. (NASDAQ:ATXS) for a mix of cash and stock. The deal represe...

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
TipRanks 5d
Here’s Why Astria Therapeutics Stock Exploded Today

BioCryst Pharmaceuticals (BCRX) has reached a deal to acquire biopharmaceutical company Astria Therapeutics (ATXS) for about $700 million in cash and stock. Thi...

Nasdaq 5d
BioCryst To Acquire Astria Therapeutics In $700 Mln Cash-and-Stock Deal

(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX), on Tuesday announced it has entered into a definitive agreement to acquire Astria Therapeutics, Inc. (ATXS),...

BioCryst To Acquire Astria Therapeutics In $700 Mln Cash-and-Stock Deal

People also own

Based on the portfolios of people who own BCRX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.